Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

NCT04944069 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

69

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
Leptomeningeal Metastasis
EGFR Activating Mutation

Interventions

DRUG: Almonertinib
DRUG: Bevacizumab

Sponsor

Second Affiliated Hospital of Nanchang University

Collaborators

[object Object]